Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update


Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3

View post:
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Related Posts